July 20, 2018 — The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first…
Publication date: Available online 19 July 2018Source: Leukemia Research ReportsAuthor(s): Grace Xiuqing Li, Lan Wang, Bassam Yaghmour, Giridharan Ramsingh, George YaghmourAbstractActivating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post…
Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations at ASCO 2018.
Authors: Michelerio A, Kirsh A, Croci GA, Colombo AA, Bernasconi P, Paulli M, Brazzelli V, Vassallo C
PMID: 30014683 [PubMed – as supplied by publisher]
ConclusionsPK parameters for hP67.6 and UC were not significantly affected by any of the available demographic factors and safety laboratory values tested as covariates (except baseline body weight). Simulations to compare GO dosing regimens (6, 7.5, and 9 mg/m2 on days 1 and 15 versus, 3 mg/m2 fractionated dosing on days 1, 4, and 7) were performed, showing that total antibody and UC trough concentrations were maintained at higher concentrations during treatment following the more frequent dosing than following the original regimen.Study Identifier0903A1-102-US.
Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)–type primary th…
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) developing in persons exposed to DNA-damaging agents for a prior cancer are often referred to as treatment- or therapy-related myeloid neoplasms (t-MN)[1,2]. t-MN constitute approximately 10-20% of all cases of AML and MDS, a proportion that may increase in the future with an increasing prevalence of cancer survivors[4,5]. Hematopoietic cell transplants (HCT) use high doses of drugs and/or ionizing radiations and can also lead to t-MN[6,7].
Daniela Magliulo, Rosa Bernardi, Samantha Messina
Downregulation of microRNA‑21 expression inhibits proliferation, and induces G1 arrest and apoptosis via the PTEN/AKT pathway in SKM‑1 cells.
Mol Med Rep. 2018 Jul 05;:
Authors: Li G, Song Y, Li G, Ren J, Xie J, Zhang Y, Gao F, Mu J, Dai J
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and may progress to acute myeloid leukemia (AML). MicroRNAs (miRNA/miRs) as oncogenes or tumor suppressors regulate a number of biological processes including cell proliferation, cell cycle and apoptosis in different types of cancer cells. Recently, it has been reported that m…
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph Rllig, MD, of the University Hospital Carl Gustav Carus, Dresde…
Daunorubicin is commonly used to treat acute myeloid leukemia (AML). In this video, Christoph Rllig, MD, of the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the results from his…